![Donald McCaffrey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermogen: 1 M $ op 31-05-2026
Mr. Donald J.
McCaffrey is a Chairman, President & Chief Executive Officer at Zenith Capital Corp.
(Alberta) and a Chairman, President, CEO & Secretary at Resverlogix Corp.
Mr. McCaffrey also served on the board at Stem Cell Therapeutics Corp.
and ProMIS Neurosciences, Inc.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2026 | 7.027.513 ( 4,4% ) | 702 751 $ | 31-01-2026 | |
RESVERLOGIX CORP. 1,53% | 02-01-2026 | 5.263.266 ( 1,53% ) | 384 218 $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| RESVERLOGIX CORP. | Algemeen Directeur | 25-04-2003 |
| ZENITH CAPITAL CORP. | Algemeen Directeur | 10-04-2013 |
| Bedrijven | Functie | Einde |
|---|---|---|
| TRILLIUM THERAPEUTICS | Directeur/Bestuurslid | 27-03-2006 |
| PROMIS NEUROSCIENCES, INC. | Directeur/Bestuurslid | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Resverlogix Corp.
 Resverlogix Corp. Pharmaceuticals: MajorHealth Technology Engages in the research and development of novel biopharmaceuticals for the treatment of grievous diseases | Health Technology |
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Zenith Capital Corp. (Alberta)
 Zenith Capital Corp. (Alberta) BiotechnologyHealth Technology Engages in the research and development of biopharmaceuticals | Health Technology |
ProMIS Neurosciences, Inc.
 ProMIS Neurosciences, Inc. BiotechnologyHealth Technology Discovers and develops precision medicine solutions for the treatment of neurodegenerative & misfolded protein diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau
